26 completed, 8 unknown, 6 recruiting, 5 terminated. 30 Phase 1, 7 Phase 2, 6 Not applicable, 1 Phase 4.
Follow Neoplasm Malignant: new trials by email Literature Review of Neoplasm Malignant trials Research Report on Neoplasm Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) Calderasib, Cetuximab - Neoplasm Malignant | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 150 | 2025-12-04 | 2026-10-07 |
| Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies. Surgery or biopsy, Blood sample - Neoplasm Malignant | Not applicable | Recruiting | Centre Antoine Lacassagne | 50 | 2025-05-02 | 2026-07-20 |
| Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA Blood sample taken for the liquid biopsy - Neoplasm Malignant | Not applicable | Recruiting | Centre Antoine Lacassagne | 238 | 2025-03-03 | 2026-07-20 |
| Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study FOLFOXIRI Protocol - Neoplasm Malignant, Colon Cancer Stage 4 | Phase 2 | Unknown | Al-Azhar University | 60 | 2024-08-17 | 2024-08-28 |
| A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors STRO-002 - Neoplasm Malignant | Phase 1 / Phase 2 | Completed | Tasly Pharmaceutical Group Co., Ltd | 19 | 2023-11-08 | 2026-04-06 |
| 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas 5-Aminolevulinic Acid (5-ALA) Gliolan®, Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA) - High Grade Glioma, Glioma | Unknown | Sociedad de Lucha Contra el Cáncer del Ecuador | 90 | 2023-06-01 | 2023-05-09 | |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Phase 1 First-in-human Study of JS014 JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody, Pembrolizumab - anti-PD-1 antibody - Neoplasm Malignant, Neoplasm, Experimental | Phase 1 | Unknown | Anwita Biosciences | 60 | 2022-02-28 | 2023-09-06 |
| A Trial of a Multimodal Lifestyle Intervention to Optimize Survivorship After Cancer Multimodal Lifestyle Program - Neoplasm Malignant | Not applicable | Completed | Pennington Biomedical Research Center | 33 | 2021-08-19 | 2026-09-17 |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Pembrolizumab, Belzutifan, Lenvatinib - Neoplasm Malignant | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 730 | 2021-08-18 | 2025-04-06 |
| Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors SAR443216 IV, SAR443216 SC - Neoplasm Malignant, Breast Cancer | Phase 1 | Terminated | Sanofi | 44 | 2021-08-16 | 2025-09-15 |
| EMPOWER 3: Improving Palliative Care Health Literacy and Utilization Multimedia Psychoeducational Intervention, Enhanced Usual Care - Cancer, Neoplasm Malignant | Not applicable | Completed | Tulane University | 172 | 2021-03-31 | 2026-10-19 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) XL102, Fulvestrant, Abiraterone - Neoplasm Malignant, Epithelial Ovarian Cancer | Phase 1 | Terminated | Exelixis | 52 | 2021-02-10 | 2024-05-14 |
| "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. CLG - Neoplasm Malignant | Not applicable | Active not recruiting | National Cancer Institute, Naples | 47 | 2021-01-18 | 2025-07-29 |
| Evaluation of a Music and Interaction Intervention on Patient Distress During Whole Body Magnetic Resonance Experimental Group, Control Group - Neoplasm Malignant | Unknown | European Institute of Oncology | 200 | 2020-12-31 | 2024-03-26 | |
| First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL SAR442257 - Neoplasm Malignant | Phase 1 | Terminated | Sanofi | 47 | 2020-07-24 | 2026-09-29 |
| AIMS Cancer Outcomes Study Neoplasms, Neoplasm Malignant | Recruiting | Advanced Integrative Medical Science Institute | 500 | 2020-05-18 | 2023-02-01 | |
| Longitudinal Analysis of Mental Disorders, Psychosocial Distress and Care Needs of Patients and Their Relatives Neoplasm Malignant | Unknown | University of Leipzig | 2000 | 2020-01-01 | 2023-05-10 | |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma IK-175, IK-175 and nivolumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 1 | Completed | Ikena Oncology | 78 | 2019-12-18 | 2024-03-15 |
Showing 20 of 49. Sign in to see all of them.
Neoplasms (49) · Neoplasm Metastasis (5) · Breast Neoplasms (4) · Stomach Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2) · Central Nervous System Neoplasms (2) · Colonic Neoplasms (2) · Endometrial Neoplasms (2) · Glioma (2) · Lung Neoplasms (2) · Neoplasms, Neuroepithelial (2) · Neuroectodermal Tumors (2)
Neoplasms by Site (11) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Breast Diseases (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Gastrointestinal Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplastic Processes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Skin Diseases (6)
pembrolizumab (4) · XL147 (3) · Cetuximab (2) · Docetaxel (2) · Fluorouracil (2) · Fulvestrant (2) · Gemcitabine (2) · Leucovorin (2) · Nivolumab (2) · SAR125844 (2) · SAR405838 (2) · XL765 (2) · aflibercept (2) · tusamitamab ravtansine (2) · 2-(2-(2-methyl-2,3-dihydroindol-1-yl)-2-oxoethyl)-6-morpholin-4-yl-3H-pyrimidin-4-one (1)
Sanofi (20) · Merck Sharp & Dohme LLC (3) · Centre Antoine Lacassagne (2) · Exelixis (2) · Advanced Integrative Medical Science Institute (1) · Al-Azhar University (1) · Anwita Biosciences (1) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · Compugen Ltd (1) · European Institute of Oncology (1) · Ikena Oncology (1) · Imperial College London (1) · Istituti Clinici Scientifici Maugeri SpA (1) · Jiangsu HengRui Medicine Co., Ltd. (1)
United States (22) · France (13) · Spain (10) · Belgium (8) · Italy (7) · Netherlands (6) · South Korea (6) · China (5) · United Kingdom (5) · Japan (4) · Australia (3) · Canada (3) · Germany (3) · Chile (2) · Czechia (2)
Alberto Valarezo Chuchuca, MD (1) · Anja Mehnert-Theuerkauf, Prof (1) · Giuseppe Petralia (1) · Gregory Friedman, MD (1) · Justin C Brown, PhD (1) · Karim Malek, MD (1) · Luigi Portella (1) · Mario Roselli (1) · Michael Hoerger, PhD, MSCR, MBA (1) · Raffaella Palumbo, MD, PhD (1) · TJ Chiou, MD (1)
PMID 10744089, PMID 11247898, PMID 15175435, PMID 15870084, PMID 16943526, PMID 17470860, PMID 18316791, PMID 19097774, PMID 19339720, PMID 19755046, PMID 21090969, PMID 24138831, PMID 25531046, PMID 26818619, PMID 28324749, PMID 28976556, PMID 30585255, PMID 32673446, PMID 35026412, PMID 35501515, PMID 37062953, PMID 37151329, PMID 37507802, PMID 37645622, PMID 40413667, PMID 40747744, PMID 41114371, PMID 41337813, PMID 42387617, PMID 42594490, PMID 42705861
2014 (2), 2023 (2), 2015 (1), 2019 (1), 2025 (1)